544 HYALURONIC ACID MANAGEMENT OF KNEE OSTEOARTHRITIS: IMPACT ON PAIN  by Taieb, C. et al.
S244 Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256
Methods: It has been set a prospective study to assess control pain and
functional performance in a group of patients affected by hip arthritis,
before and after viscosupplementation. From May 2005 to September 2009
we performed an intra articular inﬁltration into the hip of 207 patients
(108 male, 99 female), mean age 67,8 (range 40-83). Each patient re-
ceived under ﬂuoroscopic guidance one injection of highly puriﬁed sodium
hyaluronate derived from bacterial fermentation, containing 75 mg of
sodium hyaluronate per 3-ml syringe. The inclusion criteria were: hip pain,
radiographic evidence of arthritis with the articular rima at least partly
conserved, full range of motion of affected hip. All patients were evaluated
using BPI score, VAS score and Harris Hip score, pre-inﬁltration, after
three, six and twelve months after treatment. The categorical data were
summarized in terms of frequency and percentage. Continuous data where
analyzed in terms of mean, standard deviations, Student’s test. 150 patients
out of 207 were studied at six months follow-up, 121 patients out of 207
were studied at one year follow-up.
Results: Mean VAS scores before inﬁltration and at 1 year follow-up were
5.6 (range 10-6, SD 2,01) and 3.33 (range 10-3, SD 2.99) respectively
(p<0,05). Mean HHS were 44.2 (range 24-66, SD 10.4) and 76.5 (range
32-81, SD 16.4) respectively (p<0,05). Mean BPI Interference score were
27,38± (range 16-53, SD 17,68) and 14,35 (range 8-34, SD 12,60) respec-
tively (p<0,05). Fifty three patients (43%) reported at least 50% of pain
relief of pain at 6 months follow-up. Each item of BPI showed a decrease
of pain interference during daily activity. The decrease was statistically
signiﬁcant for all items (p<0,05). Particularly decreasing was observed for
pain interference with sleep (from 4,09, SD 3,15 pre inﬁltration to 1,27,
SD 1,36 at 1 year follow-up), mood (from 4,40, SD 3,17 pre inﬁltration to
2,04, SD 2,37 at 1 year follow-up), enjoy (from 3,21, SD 3,46 pre inﬁltration
to 1,27, SD 2,10 at 1 year follow-up). No local side effects or systemic
complications was observed in our series.
Conclusions: Our data show that viscosupplementation is a promising
approach for hip osteoarthritis, providing beneﬁcial effects in a long-term
follow up. The results demonstrated that it is possible to delay replacement
of the arthritic hip, but above all that hip pain could be eliminated in
patients clinically and radiographically at the limit of the indication for
surgical treatment.
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Purpose: Chronic pain or chronic pain syndrome is deﬁned as a mul-
tidimensional syndrome, when the pain expressed leads to a signiﬁcant
and progressive deterioration in the patient’s functional and relational
capacities. Knee osteoarthritis is a real public health problem. According to
data from the Framingham study, its prevalence is estimated to be 6.1% of
adults over the age of 30. This prevalence increases with age, to more than
40% after the age of 75. Knee osteoarthritis is generally not life-threatening,
but it does signiﬁcantly affect the daily lives of patients who have it and
incurs very high costs for the community
Methods: Pragmatic, longitudinal and prospective follow-up carried out
by rheumatologists in the context of their daily professional activities;
the investigator does not change the prescription or management habits.
The objective is to observe, under actual conditions of use, the pain
effect obtained, in the context of management of knee osteoarthritis, using
hyaluronic acid (injectable route).
Results: 191 patients are treated with hyaluronic acid. The average age is
64.72 years (±7.34). Average pain during activities of daily living (ADL) was
measured by means of a visual analogue scale (VAS). It is 50.12±19.32 at
inclusion.
At 6 months, this same average pain measured under the same conditions is
36.95±25.10. A third measurement at 12 months situates it at 38.10±23.19.
Pain during ADL is signiﬁcantly reduced between inclusion and month 6
(p=0.0023) and between inclusion and month 12 (p=0.0012).
With regard to pain measured at rest, it was also measured at inclusion,
at 6 and 12 months, by means of VAS. There is a signiﬁcant reduction in
pain at rest between inclusion and 6 months (p=0.0004) and the reduction
between inclusion and month 12 is also signiﬁcant (p=0.0007). At inclusion,
6 and 12 months, the average pain observed is 33.48±22.45, 19.90±19.88
and 21.64±22.94, respectively.
Conclusions: Our study, which assesses the effect on pain obtained in
the context of management of subjects with knee osteoarthritis, using
hyaluronic acid, showed a reduction in pain during ADL. This reduction
in pain, which is signiﬁcant at 6 months, then perpetuated at 12 months,
shows the relevance of the treatment protocol used by the doctors.
Therapy – Non-Pharmacologic
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Purpose: To determine the effect of Hyal-Joint® administered by twice
daily oral dosing on inﬂammation, cartilage destruction, bone resorption
and synthesis of hyaluronic acid (HA) in synovial ﬂuid (SF) that occurs in
developing type II collagen arthritis in rats.
Methods: Twenty-four female Lewis rats weighing 136-154 g were used
in this study. Rats with developing type II collagen arthritis (n=20) were
treated orally twice daily on days 0-16 of the study with vehicle (H2O;
disease control; n=10) or Hyal-Joint® (7.5 mg, BID; n=10). They were
anesthesized with isoﬂurane and given collagen injection on day 0 and
6. Nonimmunized rats (normal; n=4) were used as normal controls. All
animals received deuterium oxide (2H2O) exposure from day 16-17 to bring
the animal’s body water to a 5% water isotopic enrichment of deuterium.
Animals were terminated on study day 17. Livers, spleen and thymus were
also collected, trimmed of extraneous tissue and weighed.
Eﬃcacy evaluation was based on animal body weights, ankle diameter
expressed as area under the curve (AUC), histopathologic evaluation of
ankles and knees. Isotopic analysis of lavage samples allowed to measure
SF volumes, HA concentration and absolute HA synthesis rate in knee SF.
Results: Body weight gain was signiﬁcantly increased toward normal
for rats treated with Hyal-Joint® (24% increase) as compared to disease
controls. Ankle diameter AUC were not signiﬁcantly reduced (14%; P=0.15)
for rats treated with Hyal-Joint® as compared to disease controls. Relative
liver, thymus and spleen weights for rats treated with Hyal-Joint® were
similar to those showed by normal rats (3.559 vs. 3.583 g, P=0.80; 0.239
vs. 0.222 g, P=0.146; and 0.199 vs. 0.220 g, P=0.191; respectively), which
conﬁrmed Hyal-Joint® safety. Individual ankle and knee histopathology
parameters (inﬂammation, pannus, cartilage destruction, bone resorption)
are showed in Figures 1 and 2, respectively. Summed histopathology scores
were signiﬁcantly reduced in ankle (17%, P < 0.05) and strongly reduced in
knee (51%,P<0.01) toward normal for rats Hyal-Joint® treated
as compared to disease controls.
Collagen-induced arthritis led to a signiﬁcant increase in knee synovial ﬂuid
volume in both vehicle and Hyal-Joint® treated rats, being less pronounced
in the second. HA concentration decreased 33% with disease controls, while
maintained similar to normal values in Hyal-Joint® group. In normal rats,
absolute synthesis rate of HA into the synovial ﬂuid was 0.43 μg/h. Disease
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